Radiopharm Theranostics Limited Overview
Radiopharm Theranostics is a capital-light, clinical-stage radiopharmaceutical developer that has assembled, primarily by in-licensing from academic centres, a portfolio spanning one late-stage diagnostic and five clinical-stage or near-clinical therapeutic and imaging programs. Its strategic thesis is to compete outside the crowded PSMA and somatostatin-receptor franchises by pairing less-exploited tumour targets (fatty acid synthase, HER2, PD-L1, αvβ6-integrin, the 4Ig isoform of B7-H3, and KLK3) with a range of isotopes (fluorine-18, gallium-68, lutetium-177, terbium-161) and molecular formats (small molecules, peptides, nanobodies and monoclonal antibodies). The lead asset, RAD101, an F-18 PET tracer for distinguishing recurrent brain metastases from post-radiotherapy treatment effects, holds FDA Fast Track designation, met its Phase 2b primary endpoint in July 2026, and completed an End-of-Phase 2 meeting with the FDA in October 2026. The company's investment case is therefore a near-term Phase 3 diagnostic catalyst set against an acute funding constraint and heavy shareholder dilution.
What the company does. Radiopharm researches and develops radiopharmaceuticals — molecules that carry a radioactive isotope to a tumour-associated target — for two purposes: diagnostic imaging (PET tracers labelled with F-18 or Ga-68) and targeted radionuclide therapy (beta- or Auger-emitting isotopes such as Lu-177 and Tb-161). The FY2026 20-F describes the company as a clinical-stage radiotherapeutics company focused on diagnostic and therapeutic products for areas of high unmet medical need, with no product approved for sale and no product revenue expected until approval and launch.
Company's own characterisation (paraphrased from the FY2025/FY2026 20-F business summaries and press-release boilerplate). The company presents itself as building a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications. The FY2025 20-F summary describes six licensed platform technologies plus a joint venture with The University of Texas MD Anderson Cancer Center, with programs in Phase 1 and Phase 2 across breast, lung, pancreatic, prostate cancer, brain metastases and glioblastoma, and development activity in the United States, Australia, the European Union and other markets. Recent investor materials (July 2026) describe the company as a multi-asset platform with a Phase 3-ready imaging lead and four clinical-stage therapeutics.
Business model. Pure research-and-development model with no manufacturing, commercial or sales infrastructure. The company in-licenses intellectual property (Imperial College London / Cancer Research Technology, NanoMab Technology, Diaprost/Fredax, TRIMT, NeoIndicate, MD Anderson), funds clinical development through contract research organisations (GenesisCare, Medpace per Zacks SCR) and contract manufacturers/isotope suppliers (Siemens Healthineers, ITM, Cyclotek, TerThera and others), and aims to monetise through either self-commercialisation (most plausibly for RAD101 in the US) or partnering/out-licensing.
Revenue model and mix.
Value-chain position. Upstream innovator: target selection, molecule optimisation, clinical development and regulatory strategy. It sits between academic licensors (upstream) and isotope producers, radiopharmacies and CMOs (supply chain), with eventual customers being nuclear-medicine departments, PET imaging centres and oncologists.
Customer types and end-markets (prospective). Hospitals and imaging centres (neuro-oncology and radiation-oncology services for RAD101), oncology treatment centres (therapeutics), and payers (CMS and private insurers in the US; PBS-type regimes ex-US). Current revenue customer: one counterparty (Lantheus), i.e. 100% customer concentration.
Independent characterisation. Radiopharm is best understood as a micro-cap option portfolio on target-isotope combinations whose value is overwhelmingly concentrated in a single near-registrational diagnostic (RAD101). The therapeutic pipeline is broad but early (Phase 1 dose escalation), and the company's balance sheet — A$4.1M cash at 30 June 2026 against A$52.8M operating cash burn — means the strategic agenda is dictated by financing. Its in-licensing model has produced breadth cheaply, but carries contingent milestone obligations (A$25.8M of contingent consideration liabilities at 30 June 2026) and royalty leakage on any eventual product.
Strategy
Stated strategic themes (paraphrased from 20-F, investor presentations and releases)
-
Go beyond validated targets. Develop radiopharmaceuticals for tumours and targets outside the prostate, thyroid and neuroendocrine indications already validated by approved products, using precision-oncology rationale.
-
Pair novel targets with underused isotopes. Use F-18, Ga-68, Lu-177 and Tb-161 to improve on-target activity and efficacy.
-
Be first in clinic in each target class. Management emphasised in March 2026 that each therapeutic is intended to be first in clinical development in its niche.
-
Asset-light, partner-heavy execution. Outsource manufacturing, isotope supply and clinical operations; leverage strategic partners (Lantheus, Siemens Healthineers, MD Anderson).
-
Advance RAD101 to registration. Be Phase 3-ready by year-end 2026 and run a multi-centre, multi-country registrational trial.
-
Strategic partnering. "Ongoing strategic partnering initiatives" are a stated use of proceeds from the July 2026 raise.
Initiatives announced in the last 24 months
| Initiative | Date | Description | Source |
|---|---|---|---|
| Nasdaq listing of ADSs | Nov 2024 | Expand US investor access; no capital raised | StockTitan |
| Lantheus co-development partnership and development-services contract | Dec 2024 – FY2025 | Co-development with initial focus on a Phase 1 imaging trial; services contract in Australia | Stockhead; FY2026 Appendix 4E |
| Isotope supply security | FY2025 | Multiple supply agreements (ITM, SHINE, ANSTO, Isotopia, Cyclotek, TerThera) | Zacks SCR; FY2025 results |
| Increase control of MD Anderson JV | Aug 2024; Jan 2026 | Stake to 75% then 87.5% | FY2026 Appendix 4E |
| RV-01 and RAD402 first-in-human trials | FY2026 | Two additional Phase 1 therapeutic programs initiated | Q3 FY26 4C (Apr 2026) |
| Leerink ATM | Dec 2025 | Flexible US equity access | FY2026 20-F |
| Siemens Healthineers RAD101 supply | Apr 2026 | Phase 3 manufacturing/distribution readiness | Press release |
| Phase 3 readiness program | Oct 2026 | Executing readiness activities pending FDA minutes | 6-K 5 Oct 2026 |
Cost programs: No formal cost-reduction program announced. The 20-F notes management can delay or reduce operating activities as a cash-management lever.
ESG commitments: None published.
Management guidance and medium-term targets
| Item | Guidance | Source |
|---|---|---|
| RAD101 FDA EOP2 minutes | Within ~30 days of 1 Oct 2026 | 6-K 5 Oct 2026 |
| RAD101 Phase 3 | Phase 3-ready by YE2026; trial start targeted 4Q 2026 | 6-K 17 Aug 2026; Zacks SCR |
| RAD204 | Cohort 3 enrollment by 3Q 2026; escalation complete 1H 2027; Phase 2 in 2027 | Zacks SCR (Aug 2026) |
| RAD202 | Cohort 4 dosing (DSMC Aug 2026) | Press release 20 Aug 2026 |
| RV-01 | Cohort 2 at 70 mCi underway | Press release 26 Aug 2026 |
| Radiopharm Ventures | Final selection of two further candidates in 2026 | Half-year release Jan 2026 |
| Cash runway | Forecast to fund operations through fiscal 2027, dependent on access to additional funding | FY2026 20-F |
| Financial targets | No revenue or profitability targets issued | — |
Products & Services
No product is approved for commercial sale anywhere. All pricing is not publicly disclosed. Programs are listed in order of maturity.
RAD101 — ¹⁸F-pivalate (imaging, brain metastases)
Description: Small-molecule PET tracer targeting fatty acid synthase (FASN), an enzyme over-expressed in many solid tumours including brain metastases; labelled with fluorine-18. Licensed from Imperial College London (via Cancer Research Technology per 20-F XBRL references).
Indication: Patients with suspected recurrence of brain metastases after radiotherapy, where MRI cannot reliably distinguish viable tumour from radiation-induced treatment effects (radionecrosis).
Status: Company-sponsored US Phase 2b (N=30) completed; topline (22 Jul 2026) showed 93% (28/30) concordance between PET and MRI across evaluable lesions, meeting the primary endpoint; earlier interim reads were 92% (first 12 patients, Dec 2025) and 90% (18/20, Mar 2026). FDA Fast Track (June 2025). End-of-Phase 2 meeting held 1 Oct 2026; minutes expected around early November 2026. Late-breaking oral presentation selected for the 2026 Society for Neuro-Oncology meeting.
Key capabilities: F-18's half-life permits regional distribution from cyclotron radiopharmacies and fits existing PET infrastructure (company investor materials, July 2026).
Manufacturing/distribution: Siemens Healthineers (supply agreement, 7 Apr 2026) to manufacture and distribute F-18 RAD101 doses for the US Phase 3.
Target customer: Neuro-oncology, radiation oncology and nuclear medicine centres; company cites roughly 300,000 US patients as the addressable population (Kalkine summary of July 2026 investor deck).
Next milestone: Phase 3-readiness by year-end 2026; Phase 3 start targeted 4Q 2026 (Zacks SCR; RTTNews).
Pricing model: Not publicly disclosed.
177Lu-RAD202 — HER2-targeted nanobody (therapy)
Description: Single-domain antibody (nanobody) against HER2 conjugated to lutetium-177; licensed from NanoMab Technology.
Indication: Advanced HER2-positive solid tumours (breast, gastric and others).
Status: Phase 0/1 "HEAT" first-in-human dose-escalation trial. Dosing progressed from 30 mCi to 75 mCi (by Dec 2025), DSMC endorsed 130 mCi (Apr 2026), and a further DSMC recommendation to advance to Cohort 4 (20 Aug 2026). Initial data presented at AACR 2026 showing tumour uptake in HER2-positive lesions.
Target customer: Oncology centres treating HER2-positive metastatic disease, including post-ADC settings.
177Lu-RAD204 — PD-L1-targeted nanobody (therapy)
Description: Nanobody against PD-L1 radiolabelled with Lu-177; licensed from NanoMab.
Indication: Metastatic non-small cell lung cancer (NSCLC) and other PD-L1-positive tumours.
Status: Phase 1 dose escalation: Cohort 1 at 30 mCi, Cohort 2 at 60 mCi (DSMC May 2025), Cohort 3 at 90 mCi approved. Early signal: two of three patients in the 30 mCi cohort had stable disease for 5.5 months versus a cited historical PFS of 3.5 months on standard of care (Jan 2026 4C). Zacks SCR expects Cohort 3 enrollment completion in 3Q 2026, escalation completion in 1H 2027 and a Phase 2 start in 2027.
177Lu-RV-01 (Betabart) — 4Ig-B7-H3 monoclonal antibody (therapy)
Description: Lu-177-labelled monoclonal antibody selective for the 4Ig isoform of B7-H3, an immune-checkpoint protein highly expressed in tumours with limited expression in healthy tissue. First therapeutic from Radiopharm Ventures (MD Anderson JV).
Status: FDA IND cleared July 2025; first-in-human Phase 1/2a initiated (by April 2026); first patient of Cohort 2 dosed at 70 mCi (26 Aug 2026). Preclinical data showed tumour shrinkage and prolonged survival.
Indication: B7-H3-expressing solid tumours (multiple types).
RAD402 — ¹⁶¹Tb-anti-KLK3 monoclonal antibody (therapy)
Description: Humanised antibody against kallikrein-3 (KLK3/PSA), labelled with terbium-161 (beta plus Auger/conversion electrons); licensed from Diaprost (with Fredax).
Indication: Metastatic or locally advanced prostate cancer.
Status: Bellberry HREC approval (Nov 2025) for first-in-human Phase 1 in Australia; trial initiated by April 2026. Tb-161 supplied by TerThera (Netherlands); radiolabelling by Cyclotek (Australia).
Differentiation: Non-PSMA target and early use of Tb-161 in a company-sponsored therapeutic trial.
RAD301 — ⁶⁸Ga-Trivehexin (imaging, pancreatic cancer)
Description: Gallium-68 labelled peptide targeting αvβ6-integrin, a marker of invasion and metastatic growth associated with poor survival in several carcinomas, notably pancreatic; licensed from TRIMT (Technical University of Munich spin-out).
Status: Phase 1 imaging trial in pancreatic ductal adenocarcinoma (PDAC); positive data announced 9 Sep 2026 showing favourable safety and biodistribution and significant tumour uptake in evaluable PDAC patients. Prior to Radiopharm's program, 99 patients had been imaged under compassionate use or investigator-initiated studies without reported safety issues (BusinessNews WA, June 2024).
RAD302 — ¹⁷⁷Lu-αvβ6-integrin (therapy)
Description: Therapeutic pair to RAD301; potential in pancreatic, head-and-neck, lung and colorectal cancers.
Status: Preclinical; spending on the TRIMT family fell from A$1.88M (FY2025) to A$0.92M (FY2026).
Radiopharm Ventures follow-on candidates
- Two additional preclinical candidates showed early positive results, with final candidate selection targeted in 2026 (Jan 2026 half-year release). Zacks SCR references a candidate designated AKY-2519 in IND-enabling studies; its origin and target are not detailed in primary sources reviewed.
Other licensed / historical assets
| Asset | Status | Source |
|---|---|---|
| NeoIndicate sublicence | Minimal spend (A$0.35M FY2026); contingent consideration written to nil in FY2026 | FY2026 Appendix 4E |
| UCLA licence | No FY2026 spend | FY2026 Appendix 4E |
| Pharma15 asset | Fully impaired at 30 Jun 2026; milestones considered extremely unlikely | FY2026 20-F |
| LRRC15 mAb (now Lantheus LNTH-2403) | Divested to Lantheus (2024) | Lantheus Q2-2024 8-K |
| TROP2 nanobody (now Lantheus LNTH-2404) | Divested to Lantheus (2024) | Lantheus Q2-2024 8-K |
Services
- Development services to Lantheus (Australia), generating A$2.77M revenue in FY2026 — the company's only revenue line.
Financial Narrative
All figures A$ millions unless stated; fiscal years ending 30 June. FY2021 was a ~5-month stub from incorporation (pre-tax loss A$1.16M per StockAnalysis) and is excluded from the five-year window.
Income statement
Sources: FY2026 Appendix 4E (FY2025–FY2026 detail); FY2025, FY2024, FY2023 Appendix 4E and FY2022 Annual Report (net loss lines); FY2022–FY2024 pre-tax per StockAnalysis aggregator; FY2024 attributable loss derived from the FY2025 Appendix 4E disclosure that attributable loss fell 20.2% to A$36.70M; FY2022 revenue derived from FY2023 Appendix 4E statement that revenue rose 100% from nil.
Margins (FY2025–FY2026; revenue base too small for meaningful ratios).
Revenue CAGR FY2023–FY2026 (derived): ~112% per year — arithmetically correct but analytically meaningless given a sub-A$4M contract-services base.
Commentary. The FY2026 loss widened 48.5% (attributable +50.3%) almost entirely because R&D expense rose 81.6% to A$49.96M, reflecting simultaneous execution of one Phase 2b and five Phase 1 programs. Within R&D, A$5.27M was non-cash impairment (Pharma15 and related). Partially offsetting were a A$1.67M gain on remeasurement of contingent consideration (versus a A$4.07M charge in FY2025) and a modest gross profit on Lantheus services. G&A rose 10.8% to A$16.22M, driven by employee benefits (A$11.19M), higher insurance (A$0.34M vs A$0.11M — consistent with a US listing) and investor relations. FY2025 was the inflection where the US listing, Lantheus revenue and the capital raise of mid-2024 reshaped the P&L; FY2026 is the inflection where clinical execution outran funding.
Balance sheet
Sources: FY2026 Appendix 4E (FY2025–26 balance sheet; equity rollforwards from 1 July 2024); FY2024 Appendix 4E (FY2022–FY2024 equity rollforward and cash); FY2023 Appendix 4E (FY2022–23 cash and NTA). Accumulated losses at FY2022 are the opening FY2023 balance. Goodwill: none recognised.
Commentary. The balance sheet is debt-free but not unencumbered: A$25.8M of contingent consideration (Diaprost A$8.90M, TRIMT A$7.76M, NanoMab A$5.55M — payable in shares — Pivalate A$2.03M, MD Anderson A$1.54M) sits against A$38.2M of capitalised licences. The most important asset after cash is the A$15.88M accrued R&D Tax Incentive receivable from the Australian Taxation Office; post year-end, A$5.78M relating to the FY2025 claim was received. Working capital collapsed from A$24.9M to A$3.0M, and net tangible assets per share turned more negative, which is the arithmetic behind the going-concern material uncertainty.
Cash flow
Source: FY2026 Appendix 4E statement of cash flows. FY2022–FY2024 cash-flow detail not reproduced in the sources reviewed. FY2025 financing also included A$1.90M borrowing repayment and a A$1.69M settlement with Lind.
Commentary. Operating cash burn rose 44% to A$52.8M. Zacks SCR's analysis of the June-quarter 4C itemises FY2026 cash uses as R&D A$43.4M, staff A$11.0M, administration and corporate A$4.2M and marketing A$0.39M. Customer receipts collapsed to A$0.54M as Lantheus services were billed but not yet collected (trade receivables A$1.23M at year end) and as deferred revenue unwound.
Ratios
ROIC, net debt/EBITDA, interest coverage and the cash conversion cycle are not meaningful for a pre-revenue, debt-free developer with negative EBITDA. FY2025 ROE of -109.2% matches the figure displayed by iTiger, corroborating the derivation.
Half-year and quarterly datapoints (FY2026)
Sources: Q1 FY26 4C (via Zacks/Kalkine); Half-Year Report 31 Dec 2025 (6-K); FY2026 Appendix 4E. The half-year interim review opinion was unmodified.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Ownership | Role | Source |
|---|---|---|---|---|
Radiopharm Theranostics Limited | Australia | Parent | Listed holding/operating company; IP licensee; R&D tax-incentive claimant | FY2026 20-F |
Radiopharm Theranostics (USA), Inc. | Nevada, USA | 100% | US operations; JV partner | 1stOncology (Lantheus agreement terms); FY2026 Appendix 4E |
Radiopharm Ventures, LLC | United States | 87.5% (FY2026); 75% (FY2025); 51% at formation | JV with MD Anderson developing therapeutics on MD Anderson IP (RV-01 / Betabart and follow-on candidates) | FY2026 Appendix 4E |
Pharma15 Corporation | Not stated | Acquired Mar 2023; asset fully impaired and "other equity" derecognised in FY2026 | Former acquired IP | FY2026 20-F; FY2026 Appendix 4E |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue (AUD Mn) | 0.299 | 3.633 | 2.768 |
Segment revenue YoY growth (%) | 2.4 | 1,114.3 | -23.8 |
Segment pre-tax loss (AUD Mn) | -47.85 | -38.24 | -56.90 |
Segment operating loss (AUD Mn) | — | -38.17 | -56.78 |
Segment gross margin (%) | — | 1.1 | 9.5 |
Contribution to group revenue (%) | 100 | 100 | 100 |
Revenue by Segment and Segment Assets & Liabilities
| R&D by program (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
NanoMab (RAD202 HER2 and RAD204 PD-L1 nanobodies) | 7.185 | 15.070 |
R&D Ventures (MD Anderson JV incl. RV-01) | 5.990 | 11.041 |
hu-PSA antibody Diaprost (RAD402) | 2.925 | 7.011 |
Pivalate Imperial (RAD101) | 5.184 | 6.153 |
αvβ6 Integrin TRIMT (RAD301/302) | 1.877 | 0.918 |
Neoindicate | 0.437 | 0.352 |
UCLA | 0.226 | 0 |
Consulting fees R&D | 0.930 | 1.324 |
Amortisation of licensed IP | 2.588 | 2.699 |
Impairment losses | 0 | 5.267 |
Other | 0.172 | 0.128 |
Total R&D expense | 27.515 | 49.963 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from contracts with customers (AUD Mn) | 0 | 0.292 | 0.299 | 3.633 | 2.768 |
Cost of sales (AUD Mn) | — | — | — | 3.594 | 2.504 |
Gross profit (AUD Mn) | — | — | — | 0.039 | 0.263 |
Other income incl. R&D tax incentive (AUD Mn) | — | — | — | 10.257 | 10.734 |
General and administrative expense (AUD Mn) | — | — | — | 14.638 | 16.216 |
R&D expense (AUD Mn) | — | — | — | 27.515 | 49.963 |
Share-based payments expense (AUD Mn) | — | — | — | 1.895 | 2.406 |
Movement in contingent consideration, gain positive (AUD Mn) | — | — | — | -4.070 | 1.671 |
Operating loss (AUD Mn) | — | — | — | -38.174 | -56.784 |
EBITDA, derived = operating loss plus amortisation and depreciation (AUD Mn) | — | — | — | -35.579 | -54.078 |
Pre-tax loss (AUD Mn) | -30.38 | -34.57 | -47.85 | -38.239 | -56.896 |
Net loss after tax, total group (AUD Mn) | -30.420 | -34.611 | -47.949 | -38.342 | -56.950 |
Net loss attributable to owners (AUD Mn) | -30.420 | -34.611 | -45.99 | -36.703 | -55.149 |
Basic and diluted EPS (A$ cents) | — | — | — | -1.76 | -1.79 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Gross margin (%) | 1.1 | 9.5 |
Operating margin (%) | -1,050.6 | -2,051.5 |
EBITDA margin, derived (%) | -979.2 | -1,953.8 |
Net margin (%) | -1,055.3 | -2,057.5 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD Mn) | 26.979 | 11.699 | 18.575 | 29.117 | 4.138 |
Trade and other receivables incl. accrued R&D tax incentive (AUD Mn) | — | — | — | 10.400 | 17.447 |
Total current assets (AUD Mn) | — | — | — | 39.854 | 21.926 |
Intangible assets — licensed IP (AUD Mn) | — | — | — | 46.574 | 38.162 |
Total assets (AUD Mn) | — | — | — | 86.482 | 60.134 |
Total current liabilities (AUD Mn) | — | — | — | 14.933 | 18.897 |
Contingent consideration liabilities, total (AUD Mn) | — | — | — | 32.098 | 25.774 |
Total liabilities (AUD Mn) | — | — | — | 43.610 | 37.810 |
Borrowings, short-term (AUD Mn) | — | — | — | 0 | 0 |
Borrowings, long-term (AUD Mn) | — | — | — | 0 | 0 |
Net debt, negative = net cash (AUD Mn) | — | — | — | -29.117 | -4.138 |
Total equity (AUD Mn) | 62.963 | 45.579 | 27.353 | 42.872 | 22.324 |
Share capital (AUD Mn) | 86.759 | 97.230 | 100.682 | 176.558 | 209.933 |
Accumulated losses (AUD Mn) | 30.905 | 65.354 | 111.339 | 145.733 | 199.660 |
Working capital, derived (AUD Mn) | — | — | — | 24.921 | 3.029 |
Net tangible assets per share (A$ cents) | 2.70 | -3.82 | — | -0.16 | -0.45 |
Ordinary shares outstanding at year end (millions) | — | — | 460.367 | 2,364.950 | 3,544.216 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD Mn) | — | — | — | 5.354 | 0.536 |
Payments to suppliers and employees (AUD Mn) | — | — | — | -42.800 | -58.354 |
R&D tax incentive received in cash (AUD Mn) | — | — | — | 0 | 4.485 |
Net operating cash flow (AUD Mn) | — | — | — | -36.645 | -52.783 |
Capex on PP&E (AUD Mn) | — | — | — | 0 | 0 |
Licence-fee liability payments (AUD Mn) | — | — | — | -1.227 | -5.421 |
Proceeds from IP sale (AUD Mn) | — | — | — | 2.998 | 0 |
Net investing cash flow (AUD Mn) | — | — | — | 1.771 | -5.421 |
Free cash flow, OCF less capex (AUD Mn) | — | — | — | -36.645 | -52.783 |
Free cash flow incl. licence payments, derived (AUD Mn) | — | — | — | -37.872 | -58.204 |
Gross equity proceeds (AUD Mn) | — | — | — | 53.978 | 35.378 |
Net financing cash flow (AUD Mn) | — | — | — | 45.432 | 33.375 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ROE on average total equity, derived (%) | -63.8 | -131.5 | -109.2 | -174.7 |
ROA on average total assets, derived (%) | — | — | — | -77.7 |
Current ratio (x) | — | — | 2.67 | 1.16 |
Debt to equity (x) | — | — | 0 | 0 |
Asset turnover on average assets, derived (x) | — | — | — | 0.038 |
R&D as % of revenue (%) | — | — | 757.3 | 1,805.1 |
Key Financials
| Metric | 30 Sep 2025 | 31 Dec 2025 | 30 Jun 2026 |
|---|---|---|---|
Cash (AUD Mn) | 19.04 | 34.52 | 4.14 |
Net operating cash outflow year-to-date (AUD Mn) | — | 22.67 | 52.78 |
Half-year loss after tax (AUD Mn) | — | 28.24 | — |
Net assets (AUD Mn) | — | 49.94 | 22.32 |
Revenue Lines
| Revenue line | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Lantheus development services, Australia (AUD Mn) | — | — | 3.633 | 2.768 |
Other / unspecified contract revenue (AUD Mn) | 0.292 | 0.299 | 0 | 0 |
Total revenue (AUD Mn) | 0.292 | 0.299 | 3.633 | 2.768 |
Geographic Revenue
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
EMEA revenue (AUD Mn) | 0 | 0 | 0 |
Capital Markets Data (USD)
| Metric | 31 Oct 2025 | 30 Jan 2026 | 11 May 2026 | 31 Jul 2026 | 15 Sep 2026 | 8 Oct 2026 |
|---|---|---|---|---|---|---|
RADX ADS close (USD) | 5.26 | 5.05 | 4.00 | 3.15 | 1.52 | 1.11 |
Firm Details
| Firm | Rating / target | Date | Note | Source |
|---|---|---|---|---|
Zacks Small-Cap Research | Valuation US$12.50/ADS | 3 Aug 2026 (prior US$13.50) | Company-sponsored research | Zacks SCR |
H.C. Wainwright | Buy, US$6 target | Initiation date not confirmed | Also placement agent for the July 2026 RDO | StockAnalysis news feed |
TipRanks consensus | Average target US$18.75 | Stale; date unclear | Aggregator | TipRanks |
Share Price & Returns
| Date | Instrument | Price | Gross proceeds (AUD Mn) | Source |
|---|---|---|---|---|
Jul–Sep 2024 | Institutional placement (multiple tranches) | A$0.04 | 62.5 | FY2026 Appendix 4E share table |
Aug 2024 | Lantheus strategic placement | A$0.05 | 7.48 | Same |
Jan 2025 | Lantheus strategic placement | A$0.06 | 8.0 | Same |
Oct–Dec 2025 | Institutional placement and SPP | A$0.03 | 35.38 | Same |
Jul–Sep 2026 | Australian placement plus US RDO | A$0.015 / US$3.16 per ADS | ~12.5 | ASX 24 Jul 2026 |
Sep 2026 | SPP (up to A$6M; A$3M shortfall commitments) | lower of A$0.015 or 2.5% discount to 5-day VWAP | Not confirmed | ASX 24 Jul 2026 |
Ongoing | Leerink ATM (ADSs) | Market | Capacity up to US$9.3M (20-F) | FY2026 20-F |
Analyst Conclusions
Management guidance. No financial guidance is provided. Operational guidance: receive FDA EOP2 minutes in roughly November 2026; be Phase 3-ready for RAD101 by year-end 2026 with a trial start targeted for 4Q 2026; continue escalation in RAD202 (Cohort 4), RAD204 (Cohort 3, 90 mCi), RV-01 (Cohort 2, 70 mCi) and RAD402; and pursue strategic partnering. The 20-F states current cash is forecast to fund operations through fiscal 2027, contingent on access to additional funding.
Consensus growth expectations. No formal revenue consensus exists. Sponsored research (Zacks) applies a 25% probability of success to RAD101 in its model (Aug 2025 report).
Bull case.
-
De-risked diagnostic with a clear regulatory path. Three consecutive readouts at 90–93% concordance, Fast Track and a completed EOP2 meeting make RAD101 one of the more advanced novel brain-PET tracers; diagnostics typically carry lower development cost and higher probability of approval than therapeutics.
-
Strategic-acquirer logic. Lantheus (an existing ~8–12% holder) has publicly refocused on radiodiagnostics, and Siemens Healthineers is already the Phase 3 supplier — two natural partners or acquirers for a US brain-metastasis PET franchise.
-
Deep-value optionality. A market value near US$20M is less than book equity before the July raise and below cumulative capital invested, while five clinical programs (including a 4Ig-B7-H3 antibody owned 87.5%) provide multiple shots on goal.
Bear case.
-
Funding precedes everything. A$4.1M of year-end cash against ~A$58M of FY2026 operating and investing outflows means a pivotal Phase 3 cannot be funded without large additional capital or a partner; the going-concern material uncertainty formalises this.
-
Relentless dilution. Shares outstanding rose ~7.7x in two years, with options over 2.50B shares and ADR warrants outstanding; the latest raise was priced at A$0.015 and the ADS has fallen ~65% since.
-
Listing and pipeline sprawl risk. The ADS trades near the US$1.00 Nasdaq bid threshold, and spreading A$50M of R&D across six programs leaves each therapeutic underfunded relative to big-pharma competitors.
Key catalysts and monitorables (next 12 months).
Concluding analyst verdict. Radiopharm Theranostics enters late 2026 with a sharply bifurcated profile. Scientifically and regulatorily, it has done what a small radiopharma developer is supposed to do: RAD101 has generated a consistent 90–93% concordance signal across three Phase 2b readouts, secured Fast Track status, locked in a credible Phase 3 supply chain through Siemens Healthineers, and completed its End-of-Phase 2 meeting with the FDA. Behind it sits a genuinely differentiated, if early, therapeutic portfolio — nanobody radioligands against HER2 and PD-L1, a 4Ig-B7-H3 antibody controlled through the MD Anderson joint venture, and one of the first company-sponsored terbium-161 programs. Financially, however, the company is at its weakest point since IPO. Year-end cash of A$4.1M, an operating burn above A$50M, a going-concern material uncertainty, shares outstanding that have multiplied roughly sevenfold in two years, a large option and warrant overhang, and an ADS hovering near Nasdaq's US$1 threshold mean that equity holders are funding a pivotal trial from a position of minimal leverage. The market's verdict — a valuation around US$20M despite the positive regulatory momentum — reflects the expectation of further deep-discount issuance rather than scepticism about the science alone. Our assessment is that value realisation for current holders hinges almost entirely on a non-dilutive or minimally dilutive transaction for RAD101: a regional or global licence, co-development, or acquisition by a diagnostics-focused party. Lantheus's stated pivot toward radiodiagnostics, its existing shareholding and its development-services relationship make it the most obvious counterparty, though no transaction has been announced. Absent such a deal, the base case is continued pipeline progress accompanied by heavy dilution, with per-share upside capped. We characterise the stock as a high-risk, binary special situation.
All figures sourced as cited. Derived metrics are computed from reported figures and labelled accordingly.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background (as disclosed) | Source |
|---|---|---|---|---|
Paul Hopper | Executive Chairman; founder | Feb 2021 | Serial biotech founder/chair; born 1956; B.A. (UNSW), FAICD | Motley Fool AU; Yahoo Finance; Stockhead |
Riccardo Canevari | Managing Director and CEO | 13 Sep 2021 | — | FY2022 Annual Report; Simply Wall St |
Phillip Hains | Executive Director, CFO; previously Company Secretary | Not confirmed | Chartered Accountant; principal of The CFO Solution (now part of Acclime Australia); specialist in listed-company finance | Pharnex; iTiger. Moomoo lists him as non-executive — discrepancy flagged |
Ian Turner | Non-Executive Director | Apr 2021 | Not detailed in sources reviewed; active on-market buyer (e.g., 3M shares, May 2025) | Motley Fool AU |
Hester Larkin | Independent Non-Executive Director | 3 Feb 2022 | Managing Director of Hester Larkin Associates Consulting; prior board/trustee roles in the UK and Belgium | Motley Fool AU; FY2022 Annual Report |
Noel Donnelly | Independent Non-Executive Director | By Dec 2024 (exact date not confirmed) | MBA; received 8M director options Dec 2024 | Moomoo; Motley Fool AU |
Dr Leila Alland | Non-Executive Director | 6 Jun 2022 | M.D.; continuing status not confirmed (absent from Dec 2024 director option issue) | FY2022 Annual Report; iTiger; Moomoo |
Executive Leadership Team
| Name | Title | Notes | Source |
|---|---|---|---|
Riccardo Canevari | CEO and MD | Increased direct holding (on-market purchase of 1.5M shares at A$0.025, 2025) | Fintool |
Phillip Hains | CFO | — | iTiger |
Vittorio Puppo | Chief Operating Officer | ~30 years in pharma and devices | FY2022 Annual Report; Yahoo Finance |
Dr Dimitris Voliotis | Chief Medical Officer | Listed as CMO in current profiles | iTiger; Moomoo |
Prof. David Mozley | CMO and Scientific Advisory Board Chair (per Yahoo) | — | Yahoo Finance |
Dr Thomas H. Tulip | Chief Business Officer | Born 1953 | Yahoo; Moomoo |
Dr Scot L. Harper | SVP Clinical Operations | — | Yahoo |
Bill Regan | SVP Regulatory Strategy | — | Yahoo |
Dr Rama Abu Shmeis | SVP Chemistry, Manufacturing and Controls | — | Yahoo |
Amritha Sushil | Company Secretary | Signed the Aug 2026 Form 6-K; earlier filings signed by Phillip Hains; Nathan Jong previously listed | 6-K 28 Aug 2026; 6-K Jun 2025 |
Directors' Remuneration
| Executive | Total compensation | Basis / period | Source |
|---|---|---|---|
Riccardo Canevari | A$1.51M | Yahoo Finance "pay" field (fiscal year unspecified) | Yahoo Finance AU |
Riccardo Canevari | A$2.65M (31.8% salary, 68.2% bonus/equity) | Simply Wall St (circa FY2025) | Simply Wall St |
Vittorio Puppo | A$1.03M | Yahoo (FY unspecified) | Yahoo Finance AU |
David Mozley | A$0.77M | Yahoo (FY unspecified) | Yahoo Finance AU |
Thomas Tulip | A$0.50M | Yahoo (FY unspecified) | Yahoo Finance AU |
Paul Hopper | A$0.27M | Yahoo (FY unspecified) | Yahoo Finance AU |
Major Shareholders
| Holder | Stake | Basis |
|---|---|---|
Lantheus Holdings, Inc. | 12.16% (Jan 2025); at least ~8.0% of 30 Jun 2026 shares on a derived floor basis (283.0M shares from the Aug 2024 and Jan 2025 placements over 3,544.2M shares), plus an undisclosed participation in the Oct 2025 placement | Market Herald; FY2026 Appendix 4E share table (derived) |
Paul Hopper | Not disclosed (subscribed 82.5M shares in Sep 2024 placement; sold 1.5M Dec 2024) | Motley Fool AU |
Riccardo Canevari | ~0.9% (circa 2025) | Simply Wall St |
Other top-10 institutional holders | Not publicly disclosed in sources reviewed (ASX top-20 list appears in the Annual Report) | — |
ADS float | ~5.3M ADS free float per iTiger (date unspecified) | iTiger |
Competitive Landscape
Competitors by Segment
| Program | Competitor | Asset / approach | Positioning vs Radiopharm | Source / note |
|---|---|---|---|---|
RAD101 (brain-met recurrence imaging) | Standard of care MRI (gadolinium, perfusion) | Incumbent | RAD101 is positioned as a problem-solving adjunct where MRI is equivocal | Company materials |
RAD101 | Blue Earth Diagnostics (Bracco) | ¹⁸F-fluciclovine amino-acid PET studied for recurrent brain metastases vs radiation necrosis | — | — |
RAD101 | Telix Pharmaceuticals | Pixclara (¹⁸F-floretyrosine/FET) glioma imaging | — | Telix H1-2025 release |
Platform / commercial radiopharma | Telix Pharmaceuticals | Illuccix/Gozellix PSMA imaging, therapeutics pipeline | Scale leader from Australia; FY2025 revenue US$803.8M | Telix FY2025 results |
Platform / commercial radiopharma | Lantheus Holdings | Pylarify, Definity, NeuraCeq | Partner and shareholder; also potential competitor in diagnostics; FY2025 revenue US$1.54B | Lantheus FY2025 8-K |
Prostate therapy (RAD402) | Novartis | Pluvicto (¹⁷⁷Lu-PSMA-617), Lutathera | Entrenched PSMA standard; RAD402 targets KLK3 instead | General market knowledge |
Prostate therapy (RAD402) | Clarity Pharmaceuticals (ASX: CU6) | Copper-64/67 SAR-bisPSMA theranostics | Australian peer competing for the same investor pool | — |
Multiple solid tumours | Eli Lilly (POINT Biopharma) | Radioligand pipeline | Big-pharma capital and manufacturing | General market knowledge |
Multiple solid tumours | Bristol Myers Squibb (RayzeBio) | Actinium-225 radioligands | Alpha-emitter platform | General market knowledge |
Multiple solid tumours | AstraZeneca (Fusion Pharmaceuticals) | Actinium-225 radioconjugates | Alpha-emitter platform | General market knowledge |
Multiple solid tumours | Perspective Therapeutics | Lead-212 peptides | US small-cap peer | — |
Isotope / platform | ITM Isotope Technologies Munich | Isotopes and own pipeline | Supplier and potential competitor | Zacks SCR |
B7-H3 (RV-01) | B7-H3 antibody-drug conjugates in development across large pharma | ADC modality | Competing modality for the same target | General market knowledge |
HER2 (RAD202) | Approved HER2 ADCs and antibodies | Non-radioactive standard of care | RAD202 must show benefit in pretreated settings | General market knowledge |
Peer Comparison FY2026
| Metric | Radiopharm (FY2026, A$) | Telix (FY2025, US$) | Lantheus (FY2025, US$) |
|---|---|---|---|
Revenue | A$2.77M | US$803.8M | US$1.54B |
Revenue growth | -23.8% | +56% | — |
Profitability | Net loss A$56.95M | Net loss US$5.3M; adjusted EBITDA US$216.4M | GAAP diluted EPS US$3.41 |
R&D intensity | ~1805% of revenue | FY2026 R&D guidance US$200–240M | — |
Cash | A$4.14M | US$141.9M | US$359.1M |



